About 10% to 15% of breast cancers are triple-negative. This means they don’t have receptors for the hormones estrogen or progesterone, and don’t have too many HER2 proteins. So, hormonal therapy medicines and medicines that target the HER2 protein aren’t effective against triple-negative breast cancer. 

Chemotherapy and immunotherapy are commonly used to treat triple-negative disease. But scientists are working diligently to develop new treatments that are more precise and targeted. 

Triple-negative breast cancer expert Dr. Lisa Carey explains the latest research.

Listen to the episode to hear Dr. Carey discuss: